Stockscreener 앱 받기
0.00
100.00%
-90.00
Merus N V 주식(MRUS)의 최신 뉴스
MerusFinancial Details - Crunchbase
Merus NV stock (NL0011375928): pipeline momentum and clinical updates keep biotech in focus - AD HOC NEWS
Merus NV stock (NL0011375928): biotech share jumps after solid Q1 data and outlook - AD HOC NEWS
Merus NV stock (NL0011375928): immuno-oncology player in focus after pipeline and data updates - AD HOC NEWS
Oculis Holding Ag Announces Board and Committee Changes - marketscreener.com
FDA Approval for BIZENGRI issued to MERUS N.V. - Quantisnow
TradingKey - TradingKey
Genmab Announces Financial Results for the First Quarter of 2026 - NTB Kommunikasjon
Merus N.V. announces proposed public offering of common shares - MSN
Merus Stock Soars To All-Time High As Genmab Announces $8B Takeover — Analysts Turn Cautious, Retail Crowd Cheers The Deal - MSN
Wells Fargo Downgrades Merus N.V. (MRUS) - MSN
Goldman's 48 potential M&A candidates - MSN
Merus (MRUS) Stifel 2024 Healthcare Conference Summary - Quartr
Merus (MRUS) Investor Update Summary - Quartr
Merus (MRUS) Proxy Filing Summary - Quartr
Merus (MRUS) TD Cowen 45th Annual Healthcare Conference Summary - Quartr
Portfolio Update: Will Merus NV benefit from rising consumer demandEarnings Growth Report & Reliable Breakout Stock Forecasts - baoquankhu1.vn
GMAB SEC FilingsGenmab 10-K, 10-Q, 8-K Forms - Stock Titan
Swing Trade: Is Merus NV exposed to currency risks2026 Momentum & Breakout Confirmation Trade Signals - baoquankhu1.vn
Trade Report: Is Merus NV on track to beat earnings2026 Short Interest & Daily Momentum Trading Reports - baoquankhu1.vn
Aug Weekly: Is Merus NV being accumulated by smart money2026 Analyst Calls & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
US Market Wrap: What hedge funds are buying Merus NVInflation Watch & Reliable Intraday Trade Alerts - baoquankhu1.vn
Merus NV Stock: Genmab Acquisition Deal at $97 Per Share Reshapes Biotech Investment Landscape for N - AD HOC NEWS
Bank Watch: Is Merus NV on track to beat earningsWeekly Investment Report & Capital Efficiency Focused Strategies - baoquankhu1.vn
Bull Run: Can Merus NV reach all time highs this year2026 Buyback Activity & Safe Entry Zone Tips - baoquankhu1.vn
Genmab Agrees to Buy Cancer Drugmaker Merus for $8 Billion - MSN
Stock Recap: Can Merus NV reach all time highs this yearRate Hike & Target Return Focused Stock Picks - baoquankhu1.vn
Merus NV Stock (ISIN: NL0011375928) Gains Momentum on Bispecific Antibody Pipeline Progress - AD HOC NEWS
Merus Buyout Rumor Gets Retail Traders Buzzing — Genmab Said To Be Leading The Race - MSN
Growth Review: Is Merus NV a good ESG investment2026 Setups & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Precision Trading with Merus N.v. (MRUS) Risk Zones - Stock Traders Daily
How Merus N.V. stock reacts to bond yieldsTrade Analysis Report & Low Risk Profit Maximizing Plans - Naître et grandir
Dividend Watch: Is Merus NV being accumulated by smart moneyMarket Sentiment Review & Consistent Profit Trade Alerts - baoquankhu1.vn
Merus N.V. (MRUS) Stock Analysis: Potential Upside In The Biotech Sector - DirectorsTalk Interviews
Aug Summary: Is Merus NV a good ESG investment2025 Big Picture & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Merus N.V. (MRUS) Stock Analysis: Biotechnology Gem With 7.78% Potential Upside - DirectorsTalk Interviews
Genmab Publishes 2025 Annual Report - GlobeNewswire
Bank of America Securities Maintained a Buy Rating on Merus N.V (MRUS) - MSN
What is Merus N.V. s 5 year growth outlookWeekly Stock Summary & AI Enhanced Trading Signals - mfd.ru
Targets Report: Will Merus N.V. stock outperform tech sector in 2025Weekly Trade Summary & Reliable Momentum Entry Alerts - mfd.ru
Genmab Prepares For Two Product Launches In 2027, Both From Recent Deals - Citeline News & Insights
Is Merus N.V. stock trading near support levelsJuly 2025 PostEarnings & Intraday High Probability Setup Alerts - mfd.ru
Published on: 2026-02-10 12:58:35 - mfd.ru
Can Merus N.V. reach all time highs this year2025 Major Catalysts & Proven Capital Preservation Methods - mfd.ru
Merus N.V. (MRUS) Stock Analysis: Weighing The 7.78% Potential Upside For Investors - DirectorsTalk Interviews
Merus N.V. (MRUS) Stock Analysis: Exploring the Potential 7.78% Upside in the Biotech Sector - DirectorsTalk Interviews
Analyst Downgrade: Is Merus NV gaining market shareJuly 2025 Macro Moves & Daily Stock Momentum Reports - baoquankhu1.vn
Growth Recap: What are Can Fite BioPharma Ltd Depositary Receipts technical support levels - baoquankhu1.vn
Aug Ideas: Is Merus NV a turnaround storyJuly 2025 PreEarnings & AI Enhanced Execution Alerts - baoquankhu1.vn
Fourteen option delistings on January 21st - TipRanks
Merus N.V. (MRUS) Stock Analysis: Biotechnology Innovator With 7.78% Upside Potential - DirectorsTalk Interviews
2.25%
0.46%
자본화:
|
볼륨(24시간):